Premium
Therapy for metastatic colorectal carcinoma with a combination of methyl‐CCNU, 5‐fluorouracil vincristine and streptozotocin (MOF‐strep)
Author(s) -
Kemeny N.,
Yagoda A.,
Braun D.,
Golbey R.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800301)45:5<876::aid-cncr2820450509>3.0.co;2-x
Subject(s) - medicine , vincristine , fluorouracil , gastroenterology , colorectal cancer , surgery , cancer , chemotherapy , cyclophosphamide
Seventy‐seven previously untreated patients with measurable metastatic colorectal carcinoma were treated with a combination of methyl‐CCNU, 5‐fluorouracil (5‐FU), vincristine and streptozotocin (MOF‐Strep). The treatment schedule consisted of methyl‐CCNU, 30 mg/m 2 for 5 consecutive days q 10 weeks; 5‐FU, 300 mg/m 2 IV for five consecutive days q 5 weeks; vincristine, 1 mg IV q 5 weeks; and streptozotocin, 500 mg/m 2 IV weekly. Two (3%) patients achieved complete remission (CR); 22 (29%) patients, a partial remission (PR); and 13 (18%) patients, a minor remission (MR). The median duration of remission was eight months (range, 4–25+months) for patients obtaining CR/PR status, and six months (range, 4–15 months) for MR status. The median survival time was 14 months for patients achieving CR/PR versus seven months for non responders. Comparison with a previous study of MOF at Memorial Sloan‐Kettering Cancer Center, showed that the MOF‐Strep combination produced a significant ( P = 0.004) increase in the number of complete and partial remissions, 32% versus 11%, and in survival, 11 versus 9 months, ( P = 0.003), respectively.